We have previously reported that perfluorooctanesulfonate (PFOS) causes cell apoptosis in renal tubular epithelial cells (RTCs). Here, we extend our findings and provide evidence of epithelial-mesenchymal transition (EMT)-associated renal fibrosis caused by PFOS and the protection by L-carnitine. Our results demonstrate that PFOS increased the expression of EMT and renal injury biomarkers (eg, vimentin, Snail, Kim1, and Lcn2). In addition, PFOS caused EMT induction through Sirt1-mediated PPARc deacetylation and inactivation. L-carnitine reversed the EMT induction caused by PFOS and alleviated PFOS-mediated increases in cell migration by reactivating PPARc through the inhibition of Sirt1 activity. The critical role of Sirt1 in this process was validated by using Sirt1 overexpression, resveratrol (a pharmacologic activator of Sirt1), nicotinamide (a Sirt1 inhibitor) and siSirt1. Nicotinamide and siSirt1, but not Sirt1 overexpression and resveratrol, alleviated PFOSmediated EMT induction, suggesting that increased Sirt1 activity contributed to the alterations. Furthermore, through PPARc overexpression and pharmacologic interventions, we validated the crucial role of increased PPARc deacetylation caused by aberrant increased Sirt1 activity in RTC transformation. Similar to PPARc overexpression, rosiglitazone (a PPARc agonist) alleviated the effects of PFOS on the EMT-related features, whereas GW9662 (a PPARc antagonist) mimicked the effects. The protective effect of L-carnitine was also verified in a mouse model of chronic PFOS exposure, in which decreased EMT biomarker levels and renal fibrosis by L-carnitine were observed in Western blot and histological analyses. Accordingly, L-carnitine alleviated EMT-associated renal fibrosis caused by PFOS through a Sirt1-and PPARc-dependent mechanism.
Perfluorinated chemicals (PFCs) with hydrophobic and hydrophilic properties are man-made products that are widely used in daily consumer items (such as carpet cleaners, fire extinguishers, and baking pans). The most prevalent PFCs are perfluorooctanesulfonate (PFOS), followed by perfluorooctanoic acid (PFOA) and perfluorohexane sulfonate (PFHxS) (Cui et al., 2009) . The serum PFC levels of fluorochemical plant workers are in the 1-2 mg/l range, and the PFOS levels are 17-53 mg/l in the general public (Gilliland and Mandel, 1996; Olsen et al., 1999) . The half-life of serum elimination of PFOS in humans is approximately 5 years (Olsen et al., 2009) . Because of the threat of longterm accumulation in the human body from a contaminated environment, the potential health risk of PFCs to humans needs to be continually evaluated.
PFCs cause glial cell death, hepatomegaly, and renal cell toxicity (Wan et al., 2012; Wen et al., 2016; Zeng et al., 2011) . However, whether they induce tumorigenesis remains debatable (Chang et al., 2014b) . We previously demonstrated that PFOS exposure results in renal tubular epithelial cell (RTC) toxicity through PPARc inactivation by Sirt1-mediated deacetylation. In addition, PFCs were found to impair renal function, leading to increased uric acid levels (Shankar et al., 2011) . Although PFCs are generally considered toxic and detrimental to human kidneys, the effects of PFOS exposure on renal fibrosis, progressive renal failure, and cancer remain to be determined. Nevertheless, PFOA and PFOS suppress the expression of gapjunctional intercellular communication and connexin 43, which are correlated with tumor onset in the liver and kidneys (Hu et al., 2002) , and the carcinogenicity of PFOA has been assessed by 20 experts from 9 countries, who classified PFOA as possibly carcinogenic to humans (Group 2B) (IARC, 2014) .
Epithelial-mesenchymal transition (EMT) has been classified into 3 types: type I EMT arises during the physiologic process of ontogeny, and types II and III are pathological EMTs (Kriz et al., 2011) . Type II EMT occurs in a solid organ, when cells are damaged and then repaired by fibrotic tissue, and type III EMT arises during carcinogenesis, wherein epithelial cells are transformed into mesenchymal phenotypes (Kriz et al., 2011) . The characteristics of EMT include the loss of E-cadherin and increased mesenchymal features (eg, Snail, fibronectin, and alpha-smooth muscle actin [a-SMA] ) (Zeisberg and Neilson, 2009 ). Although EMT is generally believed to contribute to renal fibrosis, fibrosis might also occur independently of EMT (Simic et al., 2013) . In addition, whether the fibrotic process is a protective strategy for injured cells to maintain their stability or to elicit tumorigenesis remains to be clarified (Zhao et al., 2013) . Thus, understanding the mechanism underlying the involvement of EMT in PFOSmediated renal fibrosis is necessary to develop therapeutic strategies for progressive renal failure.
Sirtuin 1 (Sirt1), an NAD-dependent deacetylase, deacetylates a wide range of substrates (eg, FOXO, NFjB, p53, and plays roles in cellular processes from energy metabolism to cell survival (Davenport et al., 2014) . The reciprocal regulation of Sirt1 and PPARc has been addressed. For instance, Sirt1 promotes fat mobilization in white adipocytes by repressing PPARc (Picard et al., 2004) , and conversely, PPARc interactions with Sirt1 can modulate Sirt1 transcription by binding to the promoter of Sirt1, as a negative feedback loop in Sirt1 induction (Han et al., 2010) . In addition to ligand-mediated activation, PPARc activity is subjected to post-translational modifications (eg, phosphorylation, acetylation, sumoylation, and ubiquitination) . Although PPARc phosphorylation has been extensively studied, it remains elusive. For instance, the phosphorylation of PPARc at different sites or even the same sites results in different transcriptional modifications depending on the physiological condition and associated kinases (Tian et al., 2014) . Recent studies have indicated that PPARc can be acetylated by p300 or CBP and deacetylated by SIRT1. PPARc acetylation increases the transactivation of numerous genes in adipogenesis (Mayoral et al., 2015; Wang et al., 2008) . In contrast, the deacetylation of PPARc is associated with an increase in the gene expression of a suite of PPARc target genes in the brown remodeling of white adipose tissue (Lysine 268 and 293) (Qiang et al., 2012; Wang et al., 2016) . Therefore, it is hypothesized that other regulators, such as coactivators and corepressors, might play critical roles in modulating PPARc function.
We previously demonstrated that PPARc is a substrate of Sirt1, causing PPARc deacetylation and inactivation in PFOSmediated RTC apoptosis (Wen et al., 2016) . In contrast, PPARc activation by rosiglitazone (RGZ) and L-carnitine can prevent PFOS-mediated RTC apoptosis through suppressing Sirt1 expression. Notably, aberrant cytosolic Sirt1 retention was observed in our experimental setting (Wen et al., 2016) . Similarly, increasing evidence has demonstrated that human Sirt1 is highly expressed and accumulated in the cytoplasm of cancer cells (Stunkel et al., 2007) . Furthermore, Sirt1 phosphorylation by cyclin B/CDK1 and JNK1 increases Sirt1 nuclear localization and enzymatic activity, which are essential for the cell-cycle regulation and stress protection pathways, respectively (Nasrin et al., 2009; Sasaki et al., 2008) . However, the aberrant cytoplasmic localization of Sirt1 is regulated by the elevated PI3K/IGF-1R signaling in human cancer cells (Byles et al., 2010) . Thus, Sirt1 is implicated in a wide range of human diseases and is a major therapeutic target. However, the beneficial or detrimental roles of Sirt1 in EMT and carcinogenesis are still controversial and unknown. For instance, Sirt1 suppresses EMT in cancer metastasis and organ cytotoxicity (Simic et al., 2013) . However, Sirt1 has also been implicated in the positive regulation of prostate cancer progression (Byles et al., 2012) . Thus, whether PFOSmediated aberrant Sirt1 activation is linked to EMT activation and renal fibrosis remains to be clarified.
L-carnitine (L-trimethyl-3-hydroxy-ammoniabutanoate), a quaternary ammonium compound, is cellularly synthesized from methionine and lysine (Steiber et al., 2004) . In lipid catabolism, L-carnitine transports fatty acids from the cytosol into the mitochondria for processing. The antioxidative activity of L-carnitine occurs through the induction of enzymes, including eNOS, HO-1, and SOD (Miguel-Carrasco et al., 2010) ; it then protects cardiomyocytes and endothelial cells from oxidative stress by reducing lipid peroxidation in the membrane (Pisano et al., 2010) . Furthermore, we previously revealed that gentamicin-induced apoptosis in RTCs can be alleviated by L-carnitine through PPARa activation in a prostaglandin I2-dependent manner (Chen et al., 2009) . Recently, PPARc activation by L-carnitine was also shown to reduce hypertension-associated renal fibrosis (Zambrano et al., 2014) .
As an addition to our previous findings on unraveling the detrimental effects of PFOS in RTC apoptosis, we explored the mechanism underlying the effects of PFOS on RTC EMT induction and renal fibrosis, for which the protective effect of L-carnitine was assessed both in vitro and in vivo.
MATERIALS AND METHODS
Cell culture and reagents. Rat RTCs (NRK-52E) were purchased from the Bioresource Collection and Research Center (Hsinchu, Taiwan). Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and grown to 85%-95% confluence before use. DMEM, FBS, and tissue culture reagents were obtained from Life Technologies (Gaithersburg, Maryland, USA). Cells from passages 5-15 were used. GW9662 was acquired from Enzo Life Science Inc. (Farmingdale, New York, USA). All other chemicals were reagent grade and were obtained from Sigma-Aldrich (St. Louis, Missouri, USA). The concentrations of the chemicals and endurance of the treatments for each assay were according to our previous publications (Chang et al., , 2012 Hsu et al., 2014) or pilot studies.
Western blot analysis and Sirt activity assay. RTCs were seeded in 6-or 10-cm 2 dishes after the indicated treatments. The cells were harvested for total cell lysates or partitioned into cytosolic and nuclear fractions by using NE-PER TM nuclear extraction reagents (Pierce, Rockford, Illinois, USA) with the addition of protease inhibitors, according to the manufacturer's instructions. Antibodies for PPARc, Sirt1, Bcl-xL/xS, pan-acetylated, a-tubulin and lamin A/C (1:500 Santa Cruz Biotechnology, Santa Cruz, California, USA), E/N-cadherin, fibronectin, vimentin, Zo-1, Snail (1:500 GeneTex, Inc. Irvine, California, USA), glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 1:2,000, Ab Frontier, Seoul, Korea), and b-actin (1:500, Millipore, Burlington, Massachusetts, USA) were included in the assay. Cell lysate (50 mg) was electrophoresed on an 8%-10% sodium dodecylsulfate (SDS)-polyacrylamide gel and was then transblotted onto a Hybond-P membrane (GE Healthcare, Hong Kong). The subsequent procedures were described elsewhere (Chang et al., 2014a) . Sirt activity was determined using a Sirt activity/inhibition assay kit (Epigentek Group Inc. Farmingdate, New York, USA), according to the manufacturer's instructions.
Transfectants of Sirt1 and PPARc1, and reverse-transcription and quantitative polymerase chain reaction. The pcDNA3.1 plasmid containing human Sirt1 was a gift from Dr. Lin Heng (Taipei Medical University, Department of Physiology, Taipei, Taiwan). The pSVSport plasmid containing full length cDNA of murine PPARc1 was a gift from Dr. Lin Teng-Nan (Academia Sinica, Institute of Biomedical Sciences, Taipei, Taiwan), which had been purchased from Addgene (Cambridge, Massachusetts, USA). The total RNA was prepared from cultures by using an RNeasy Mini kit (Qiagen, Hilden, Germany), and the mRNAs were reverse-transcribed into cDNA using oligo-dT and reverse transcriptase (Invitrogen, Carlsbad, California, USA). The genes of interest were analyzed by using reverse transcription-(RT-) and quantitative-(Q-) PCR as described in Chang et al. (2017) , with minor modifications. The sequences of primer pairs for the amplification of each gene are listed in Table 1 : glutathione peroxidase-1 (Gpx-1), kidney injury molecule-1 (Kim1), neutrophil gelatinase-associated lipocalin (Lcn2), N-acetyl-b-glucosamidase (Nag), and so on. Five micrograms of total RNA from the RTC extracts was used.
The expression of the housekeeping gene GAPDH or b-actin was analyzed and used to demonstrate the presence of the same amount of total cDNA in each RNA sample.
Cell migration assay. Transwell migration assay was performed to evaluate the migration of the RTCs, as described previously (Hsu et al., 2014) , using 24-well transwell units with 8-mm polyvinylpyrrolidone-free polycarbonate filters (Dow Corning, Midland, Michigan, USA) that had been briefly dipped with 1% gelatin. Pretreated cells (1 Â 10 4 cells) were seeded in a medium containing 2% FBS and pretreated with 10 mM L-carnitine overnight and 10 mM nicotinamide (NAM), 10 mM resveratrol, 3 mM RGZ, or 5 mM GW9662 for 1 h, followed by a 500 nM PFOS challenge in the upper compartment. A medium containing 10% FBS was added to the lower compartment. The transwell plates were incubated at 37 C for 20 h in a humidified atmosphere containing 5% CO 2 . Cells migrating to the lower surface of the membrane were detected through Giemsa staining by using a light microscope.
Gelatin zymography. PFOS-treated RTCs were evaluated for the gelatinase activity of matrix metalloproteinase (MMP)-2 and MMP-9 in a conditioned medium, through gelatin zymography using a modified SDS-PAGE gel (Kim et al., 2016) . In brief, the conditioned medium was centrifuged (10,000 Â g, 5 min, 4 C),
and an equal volume (25 ml/5 ml at 10 cm 2 ) was mixed with nonreducing sample buffer (240 mM Tris-HCl at pH 6.8, 40% glycerol, 0.2% bromophenol blue). The mixture was then electrophoresed on a 7.5% SDS-PAGE gel with 0.1% gelatin at room temperature. The resulting gel was washed 3 times at room temperature with washing buffer I (50 mM Tris-HCl at pH 7.4, 2% Triton-X100) for 15 min and then washed 3 times with buffer II (50 mM Tris-HCl at pH 7.4) for 5 min, followed by use of the developing buffer (50 mM Tris-HCl at pH 7.4, 0.02% NaN 3 , 0.02 mM ZnCl 2 , 5 mM CaCl 2 , 200 mM NaCl) at 37 C for 24 h and subsequent staining and destaining with conventional solutions. The molecular size of each gelatinolytic band was evaluated using protein standard ladders (Thermo Fisher Scientific, Waltham, Massachusetts, USA), and the bands were photographed using an image analysis system (UVP BioChemi, UVP LLC, Upland, California, USA).
Animal treatments and histological examination. All animal study procedures were conducted in accordance with the Taipei Medical University Animal Care and Use rules (licenses No. LAC-2015-0207) and Institutional Animal Care and Use Committee or Panel (IACUC/IACUP). Eight-week-old male Balb/c mice weighing 20-25 g were obtained from the Research Animal Center at National Taiwan University (Taipei, Taiwan). The animals were housed in a central facility, subjected to a 12-h lightdark cycle, and were provided regular rat chow and tap water. Stock solution of 100 mg/ml PFOS was prepared by dissolving in Sirt1  TCTTGGAGACTGCGATGTCA  GAGGTGTTGGTGGCAACTCT  161  Gpx-1  AGAAGTGCGAGGTGAATGGT  CGGGGACCAAATGATGTACT  127  TGFb1  TGCTTCAGCTCCACAGAGAA  TGGTTGTAGAGGGCAAGGAC  182  Collage1  TGGTGCTAAGGGTGAAGCTG  GCAATACCAGGAGCACCATT  188  Kim1  CGCAGAGAAACCCGACTAAG  AAAGCTCAGAGAGCCCATC  132  Lcn2  CACCCTGTACGGAAGAACC  GGTGGGAACAGAGAAAACGA  113  Nag  TTAACCTCGAACCGCAGTG  GTCCCATAAGCGTCCTGGTA  301  b-actin  AGCCATGTACGTAGCCATCC  TCTCAGCTGTGGTGGTGAAG  227  GAPDH  AACTTTGGCATTGTGGAAGG  TGTTCCTACCCCCAATGTGT  223 DMSO, which was subsequently diluted to 0.5 and 0.05 mg/ml by phosphate-buffered saline for subsequent intraperitoneal injection to mice. Selection of the dose and period were based on a study of PFOS by Lau et al. (2003) and our previous study of L-carnitine (Sue et al., 2014; Wen et al., 2016) . Balb/c mice were separated into control, PFOS (0.1, 1 mg/kg), L-carnitine (50 mg/kg), and L-carnitine (50 mg/kg) þ PFOS (0.1, 1 mg/kg) groups. To evaluate the harmful effect of PFOS in murine kidneys, the mice were alternatively intraperitoneally injected with L-carnitine or PFOS every other day and 2 times/week for 3 months (n ¼ 5). At the end of the treatment period, the animals were intramuscularly anesthetized using a combination of ketamine (8 mg/100 g body weight), xylazine (2 mg/100 g), and atropine (0.16 mg/100 g). Blood samples were collected to measure the serum levels of creatinine and urea nitrogen by using Fuji Dri-Chem slides (Fujifilm, Tokyo, Japan). One kidney from each mouse was removed through laparotomy and snap-frozen in dry ice for the Western blot analysis of EMT-associated markers. The other kidney was fixed in 4% formalin, washed in phosphate-buffered saline and serially dehydrated in increasing concentrations of ethanol before being embedded in paraffin. Serial 5-mm sections of these samples were stained with hematoxylin and eosin (HE), a terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL), periodic acid-Schiff (PAS), and Masson's trichrome, examined by light microscopy, and assessed for the kidney morphology and fibrosis. The histological analysis of the kidney was modified according to suggestions by Kurus et al. (2009) defined tubular injury as tubular dilation, tubular atrophy, vacuolization, the degeneration and sloughing of tubular epithelial cells, or thickening of the tubular basement membrane. Only cortical tubules were used in the scoring system, where 0 ¼ no tubular injury; 1 ¼ <10% of tubules injured; 2 ¼ 10%-25% of tubules injured; 3 ¼ 26%-50% of tubules injured; 4 ¼ 51%-75% of tubules injured; and 5 ¼ >75% of tubules injured. Kidney sections stained with Masson's trichrome were assessed by a scoring system (Pichler et al., 1995) of 0-3 for the presence of collagen in 10 systematically sampled areas per section, where 0 ¼ no change; 1 ¼ mild fibrosis; 2 ¼ moderate fibrosis; and 3 ¼ severe fibrosis with severe interstitial thickening between the tubules. Masson's trichrome stained renal sections were assessed for the presence of collagen in 13 non-overlapping microscopic fields per animal. Optical density values of collagen fibers were processed using Image Pro Plus 6.0 (Media Cybernetics; Bethesda, Maryland, USA). Renal tissue slides were also stained for EMT markers including E-cadherin, vimentin and fibronectin by immunofluorescence staining and the subsequent procedures have been described previously (Chang et al., 2014a) . The histological examination was performed in a singleblind manner by a pathologist.
Statistical analysis. Data from at least 3 experiments are presented as the mean 6 SEM. p values for the differences in the means between 2 conditions were calculated using unpaired Student's t-test, and the differences among multiple groups were tested using analysis of variance (one-way ANOVA and Fisher's test). p < .05 was considered significant.
RESULTS

Concentration-and Time-Dependent Effects of PFOS on EMT Induction in RTCs
To examine the EMT effect of PFOS in RTCs, cells were treated with increasing concentrations of PFOS (0-500 nM) or by using varying durations of treatment; the resulting cell lysates were harvested and analyzed for targets involved in EMT induction through Western blotting and MMP2 and 9 activity through zymography. Figure 1A shows that PFOS concentrationdependently increased MMP2/9 activities and the expression of EMT markers (eg, N-cadherin, vimentin and Snail), and reduced Zo-1 expression. These effects were associated with PPARc deacetylation in total and cytosolic cell lysates through increasing Sirt1 expression and cytosolic Sirt1 sequestration, accompanied by reduced Sirt1 phosphorylation (p-Sirt1).
Whether cytosolic Sirt1 executes its deacetylation activity was validated by demonstrating that PFOS predominantly increased Sirt1 activity in cytosol in a Sirt activity assay ( Figure  1B) . Consistent with the EMT effect of PFOS, a transwell assay showed that PFOS concentration-dependently increased RTC cell migration ( Figure 1C ). In addition, Figure 1D indicates that PFOS time-dependently altered EMT markers (eg, TGFb1, collagen1, E/N-cadherin, vimentin, fibronectin, Snail, and Zo-1), with concomitantly increased cytosolic Sirt1 sequestration in the analysis and Western blots and RTPCR. Furthermore, whether RTCs were damaged by PFOS exposure was examined through QPCR analysis for renal injury markers (eg, Kim1, Lcn2, and Nag); the results revealed that PFOS (500 nM) significantly increased the mRNA levels of Lcn2 and Kim1 but not N-acetyl-b-glucosamidase (Nag), a lysosomal enzyme, after 24 h of treatment ( Figure 1E ). The present findings suggested that the mRNA levels of KIM-1 or NGAL could detect PFOS-induced renal injuries after 24-h treatment. The insensitivity of NAG as an injury marker might be because the conditions (eg, timing and dosing) are not optimized for NAG or because the lysosomal activity showed no apparent increase in PFOS-treated RTCs.
Protective Effect of L-carnitine in PFOS-Mediated EMT Induction Through PPARc/Sirt1-Dependent Mechanisms Sirt1 phosphorylation by various kinases (eg, JNK1, cyclin B/ CDK1) regulates Sirt1 nuclear translocation, stability, and activity. Thus, whether the reduced nuclear translocation of Sirt1 by PFOS resulted from the suppression of these signaling pathways was examined through Western blot analysis in RTCs subjected to PFOS treatment at the indicated time points. Figure 2A shows that PFOS attenuated Sirt1 phosphorylation level, accompanied by the reduction of JNK1 phosphorylation at 30 min and cyclin B/CDK1 levels at 6 h in RTCs, which by contrast can be prevented by additional L-carnitine treatment through PPARc reactivation by reducing Sirt1 expression and its cytosolic sequestration in PFOS-treated RTCs. Consistent with our previous study (Wen et al., 2016) regarding the protective effect of L-carnitine in PFOS-treated RTC apoptosis, the results of Western blot and RTPCR analysis in Figure 2B demonstrate that L-carnitine reduced TGFb1, collagen1, vimentin and Snail but increased E-cadherin and Zo-1 expression. L-carnitine consistently reduced cell migration, another characteristic feature of EMT that is caused by PFOS, as observed in the transwell assay ( Figure 2C ). In RTCs, EMT induction is caused by PFOS through aberrant Sirt1 localization and activation.
The molecular actions of L-carnitine involved in protection against PFOS-mediated EMT induction were compared with those of NAM, a Sirt1 inhibitor. Similar to the effect of NAM, the results of in Figure 3A indicate that the protective effects of L-carnitine and NAM on PFOS-mediated EMT induction occurred through the reactivation of PPARc by increasing its acetylation. This further led to Sirt1 downregulation by a negative feedback mechanism and subsequently reduced EMT induction in PFOS-treated RTCs. In addition, RTCs were transfected with pcDNA-Sirt1 or siSirt1 ( Figure 3B) , and pretreated with resveratrol, a Sirt activator, or NAM ( Figure 3C ) followed by PFOS challenge, and the effects were compared. Western blot analysis revealed that contrary to the effect of siSirt1 and NAM, pcDNA-Sirt1 and resveratrol mimicked the effect of PFOS on Sirt1 upregulation and PPARc deacetylation and inactivation, resulting in increased expression of EMT biomarkers, including vimentin, Snail, and fibronectin (Figs. 3B and C). Similarly, PFOS increased RTC cell migration ( Figure  3D ) and renal injury markers (eg, Kim1 and Lcn2) ( Figure 3E ), which can be modulated by these pharmacologic interventions: NAM alleviated the effect and conversely resveratrol exacerbated it.
Role of PPARc in PFOS-Mediated EMT Induction
We also validated the involvement of PPARc inactivation in PFOS-mediated EMT induction through genetic and pharmacologic interventions. Before the PFOS challenge, cells were transfected with pSV-PPARc to gain PPARc function or treated with RGZ (a PPARc agonist) and GW9662 (a PPARc antagonist) to verify their effects on PFOS-mediated EMT induction and cell migration. Figure 4A shows that, similar to L-carnitine, PPARc overexpression can alleviate the effect of PFOS on EMT induction in RTCs, resulting in decreased vimentin but increased Zo-1 levels. These results suggested the critical role of gaining PPARc function in preventing RTCs from PFOS-mediated EMT induction ( Figure 4A ). In addition, we demonstrated the effect of PFOS in reducing the transactivation ability of PPARc; mRNA level of glutathione peroxidase-1 (Gpx-1), a downstream target of PPARc Figure 1 . Concentration-and time-dependent effects of PFOS on EMT induction and cell injury in RTCs. Cells were treated with increasing concentrations (0-500 nM) of PFOS for 6 h. A, Total cell lysates, cytosolic-nuclear fractions, or conditioned media were analyzed for the indicated proteins through Western blot analysis or zymography. B, Cells with 0-500 nM of PFOS treatment for 6 h were harvested and fractionated into cytosol and nuclei, in which 10 mg of cell lysates for each sample were subjected to Sirt activity analysis using an ELISA assay kit, according to the manufacturer's instructions. C, The promigratory effect of PFOS in RTCs was assessed using a transwell assay. After 20 h of treatment, cell migration was observed using a microscope with a CCD camera attached (n ¼ 4). Magnification Â100. D, Cells were treated with 500 nM of PFOS for 6-24 h. Samples were prepared as described previously. Data from a representative experiment are shown. The bar chart shows the normalized intensities of each protein band. Lamin A/C and GAPDH were used as internal controls for the nuclear and cytoplasmic fractions, respectively, and GAPDH also served as a loading control for whole cell lysates. Data are presented as the mean 6 SEM of 3 independent experiments. E, Cells were treated with 500 nM of PFOS for 24 h and harvested for total RNA, followed by QPCR analysis of renal injury biomarkers. Results are expressed as the mean 6 SEM (n ¼ 3). Unpaired Student's t-test was performed to compare treatment means with the control (p < .05 vs control) in A, B and E, and the comparisons in D were subjected to ANOVA followed by Fisher's test.
Significant difference: *p < .05 versus the control of C0; # p < .05 versus the control of each respective time point.
based on promoter analysis, was inhibited by PFOS and GW9662, but induced by RGZ using both GAPDH and b-actin as internal controls ( Figure 4B ). Regarding pharmacologic interventions, RGZ increased PPARc acetylation, whereas GW9662 reduced PPARc acetylation through the modulation of Sirt1 mRNA and protein expression levels ( Figure 4B ). The negative feedback of PPARc activation on Sirt activity was examined by using a Sirt activity assay, which demonstrated that PPARc activation by RGZ inhibited Sirt activity; conversely, PPARc inactivation by GW9662 failed to inhibit PFOS-mediated Sirt1 upregulation/activation. Furthermore, RGZ alleviated the effect of PFOS on the induction of EMT markers, including N-cadherin, Snail, and tin and GAPDH as internal controls, whereas total cell lysates of 30 min and 6 h, and cytosolic-nuclear fractions of 6 h PFOS treatment were analyzed through Western blot or Sirt activity assays for indicated targets. GAPDH or a-tubulin was used as internal controls for whole cell lysates or cytosolic fraction, and Lamin A/C was used as a control for nuclear fraction. B, Cells with PFOS treatment for 6 h as in A were harvested and analyzed through RT-PCR and Western blot analysis for EMT-related targets. Data are in triplicates and are expressed as mean 6 SEM (n ¼ 3). Comparisons were subjected to ANOVA followed by Fisher's test (*p < .05 vs control group; # p < .05 vs PFOS treatment only). C, The migration of RTCs was evaluated in 24-well microchemotaxis chamber plates 20 h after the indicated treatments. The migratory cells treated with the PFOS or L-carnitine were photographed at Â 100 magnification with DMSO alone as a control (n ¼ 4). Cells were pretreated with L-carnitine overnight or NAM for 2 h, followed by a PFOS challenge for 6 h. The resulting cells were harvested and analyzed using Western blotting for the EMT-related proteins. B, To validate the critical role of Sirt1 in this event, Sirt1 was knocked down or expressed by overnight transfection of a small interfering RNA (siRNA) duplex containing the Sirt1 mRNA sequence (GCGGAUAGGUCCAUAUACUTT) or pcDNA3.1-Sirt1. C, Resveratrol (RSV; a Sirt1 activator) was included for comparison with the effect of NAM (a Sirt1 inhibitor) in RTCs. Cells were pretreated with RSV and NAM for 2 h, followed by PFOS treatment for 6 h. The bar chart shows the normalized intensity of each protein band. GAPDH or a-tubulin was used as an internal control for whole cell lysates. The effects of Sirt1 as an agonist and antagonist in cell migration (D) and in protecting RTCs from PFOS-mediated injury through QPCR analysis (E) were examined as described in Figure 1E . Cell migration data from a representative experiment are shown (n ¼ 4). Western blot and QPCR results are expressed as mean 6 SEM (n ¼ 3). Comparisons were subjected to ANOVA followed by Fisher's test. Significant differences were indicated by *p < .05 versus the control and # p < .05 versus PFOS treatment only.
vimentin, whereas GW9662 mimicked the effect of PFOS on RTCs ( Figure 4B ). Similarly, PPARc reactivation by RGZ can prevent a PFOS-mediated increase in cell migration. Conversely, PPARc inactivation by GW9662 exacerbated the effect of PFOS on increased cell motility ( Figure 4C ).
PFOS Contribution to Renal Fibrosis In Vivo Through EMT Induction
To evaluate the long-term toxicity of PFOS in murine kidneys, mice were alternatively intraperitoneally injected with L-carnitine (50 mg/kg) and 0.1 and 1 mg/kg doses of PFOS every other day, 2 times/week for 3 months, as described in Materials and Methods. The dose was selected based on previous studies of PFOS (Lau et al., 2003; Wen et al., 2016) , and the endurance was prolonged to 3 months to mimic the chronic PFOS exposure experienced by fluorochemical plant workers. The findings of our animal study are consistent with the in vitro findings. On histological examination using HE staining and TUNEL with methyl green nuclear counterstaining, mice with PFOS exposure exhibited deterioration in renal structure; increased infiltration of macrophages and small lymphocytes (blue arrow); reduced renal tubular integrity, with the drop out of some epithelial cells and enlarged lumens of proximal or distal convoluted tubules (green arrow); loss of cytoplasm (black arrow); and increased apoptotic cell death (red arrow). Additionally, murine kidneys with PFOS insult exhibited fibrosis, with increased collagen deposition (yellow arrow) observed using Masson's trichrome staining and increased deposition of cytoplasmic glycogen and lipids (pink arrow) observed using PAS staining ( Figure 5A ). (a PPARc agonist) and GW9662 (GW; a PPARc antagonist) for 1 h (B), followed by PFOS challenge for 6 h. Cells were harvested and analyzed for EMT-related proteins through Western blot/RTPCR/zymography analysis and Sirt activity through a Sirt activity assay. C, The effect of PPARc agonist or antagonist in RTC migration was determined through a transwell assay (n ¼ 4), as described previously. Data from a representative experiment are shown. Results are expressed as mean 6 SEM (n ¼ 3).
Comparisons were subjected to ANOVA followed by Fisher's test. Significant difference: *p < .05 versus the control; # p < .05 versus PFOS treatment only.
Semi-quantitative bar graphs were included below Figure 5A , based on the grades of tubular injury and interstitial fibrosis as well as the optical density of collagen. Furthermore, immunofluorescence staining revealed that PFOS decreased E-cadherin levels but increased vimentin and fibronectin expression in renal tissues. These effects can be significantly alleviated in mice by using additional L-carnitine treatment, suggesting the protective effect of L-carnitine in PFOS-mediated renal impairment ( Figure 5A ). Similarly, Western blot analysis showed that the altered levels of Sirt1 and acetylated PPARc, and elevated EMT markers, including N-cadherin, Snail, and fibronectin, in the PFOS groups were significantly reduced in mice with additional L-carnitine treatment ( Figure 5B) . Similarly, in agreement with our previous findings (Wen et al., 2016) , PFOS increased renal cell apoptosis by increasing the ratio of Bcl-xS to Bcl-xL in this experimental setting, which could be prevented by additional L-carnitine treatment ( Figure 5B ). In addition, in QPCR analysis, mice subjected to the PFOS challenge had significantly increased vimentin (EMT biomarker), TGFb1 and collagen1 (renal fibrosis), and Lcn2 (renal injury marker) levels compared with the control mice ( Figure 5C ). Furthermore, biochemical assays for renal function demonstrated that mice subjected to PFOS insult exhibited increased serum urea nitrogen levels, which is indicative of renal dysfunction in PFOS insult ( Figure 5D ). These effects of PFOS can be significantly alleviated by additional L-carnitine treatment.
DISCUSSION
We have previously demonstrated that PFOS causes RTC apoptosis through Sirt1-mediated PPARc inactivation. We extended our previous findings and revealed the effects of PFOS on EMT induction in vitro and in renal fibrosis in mice with chronic exposure to PFOS. Similar to our previous finding of the protective effect of L-carnitine in PFOS-mediated RTC apoptosis, L-carnitine alleviated PFOS-mediated EMT induction and renal fibrosis by restoring the function of Sirt1 and PPARc. Here, we demonstrated that PFOS triggered the induction of EMT markers (eg, Ncadherin, Snail, vimentin, and fibronectin) and downregulated Zo-1 expression, a tight junction molecule; conversely, this can be prevented by additional L-carnitine treatment. L-carnitine can reduce the increased cytosolic sequestration of Sirt1 and reactivate PPARc by increasing PPARc acetylation through suppression of Sirt1 activity in PFOS-treated RTCs (as summarized in Figure 6 ). The results presented in this study showed that the extent of PPARc acetylation was significantly reduced in RTCs that faced the PFOS challenge (Figs. 1-5) . Although reduced Sirt1 nuclear translocation by PFOS was expected to increase nuclear PPARc acetylation, we did not observe apparent increases in the acetylation of PPARc (Figs. 1A and 2A ), other than histone (H)-3 and H-4 acetylation, in nuclei (Supplementary Figure 1A) . Our findings might suggest that although Sirt1 is reduced in nuclei, histones or other unidentified co-activators/co-repressors might compete with PPARc for acetylation by CBP or other HAT, or conversely deacetylation by Sirt1 in PFOS-treated RTCs. However, this speculation remains to be verified. Moreover, we also observed that increased cytosolic Sirt1 is associated with H3/H4 deacetylation in the cytosol (Supplementary Figure 1A) , suggesting that Sirt1 might execute its deacetylation activity not only in the nuclei but also in the cytosol. Furthermore, we also observed that PFOS increased the recruitment of NCoR, a PPARc corepressor, to a complex of Sirt1 and PPARc in a Co-IP assay (Supplementary Figure 1B) . This might be correlated with the reduced transcriptional regulation of Gpx-1, a downstream target of PPARc, in response to PFOS and GW9662 treatment ( Figure 4B ). The reduced PPARc acetylation and activity in PFOStreated RTCs was in accordance with our previous study (Wen et al., 2016) , showing the reduction of PPRE transactivation activity through a luciferase reporter assay and the downregulation of anti-oxidative enzymes through RT-PCR and ChIP assays.
We further explored the mechanism underlying the effect of PFOS in the increased cytosolic sequestration of Sirt1 in RTCs. Consistent with the findings of a study describing the potential mechanisms underlying the decreased nuclear translocation of Sirt1 in vitro (Byles et al., 2010; Nasrin et al., 2009; Sasaki et al., 2008) , we demonstrated that the reduced JNK1 phosphorylation and cyclin B/CDK1 caused by PFOS might be correlated with this effect. In addition, we used genetic knockdown of Sirt1 and PPARc overexpression, and pharmacologic intervention with NAM (a Sirt1 inhibitor) and RGZ (a PPARc activator) to validate their protection in RTCs through the alleviation of PFOSmediated EMT induction and concomitant reduction of cell migration. Conversely, resveratrol (a Sirt1 activator) and GW9662 (a PPARc inhibitor) failed to inhibit these effects, suggesting that PFOS-mediated EMT induction in RTCs occurred through PPARc inactivation by Sirt1-mediated PPARc deacetylation. Although Sirt1 inactivated PPARc through deacetylation, PPARc reactivated by L-carnitine and RGZ can downregulate Sirt1 in a negative feedback mechanism (Figs. 2A and 4B) , suggesting that reciprocal regulation occurs.
EMT is believed to mainly contribute to the incidence of renal fibrosis. However, this concept was recently challenged by a study demonstrating that epithelial cells do not give rise to interstitial myofibroblasts in wild-type mice after injury . Several issues in the literature continue to be debated, namely (1) the existence of EMT in in vivo kidneys; (2) the contradictory roles of EMT in the incidence of renal fibrosis; (3) the interwoven relationship between renal fibrosis and carcinogenesis; and (4) the unequivocal roles of Sirt1 in EMT, renal fibrosis, and carcinogenesis (Humphreys, 2010; Simic et al., 2013; Zhao et al., 2013) . In addition, the double-edged sword of Sirt1 in organ fibrosis and tumor onset has been discussed in the literature (Frazzi et al., 2013) . In other words, the beneficial or detrimental roles of Sirt1 in organ fibrosis and tumor onset are still contradictory and seemingly depend on the different experimental settings being employed across the varying cells or tissues (Byles et al., 2012; Simic et al., 2013) . Although the roles of EMT and Sirt1 in renal fibrosis remain uncertain, the experimental settings of both our in vitro and in vivo studies suggested that PFOS is correlated with increased renal fibrosis, at least in part, through EMT, accompanied by increased cytosolic Sirt1 sequestration. The finding might conflict with the concept of the protective role of Sirt1 in renal fibrosis (Simic et al., 2013) . However, our findings were validated by using NAM, a Sirt1 inhibitor, to protect RTCs from EMT induction by PFOS. Thus, the molecular action of PFOS was linked to PPARc inactivation, which can be prevented by RGZ (a PPARc activator) and L-carnitine. The in vitro findings were validated in vivo in mice with chronic exposure to PFOS for 3 months. Based on a study measuring serum PFOS levels in adult mice subjected to PFOS for 28 days (Fair et al., 2011) , the serum PFOS levels at 0.1 and 1 mg/kg of treatment for 3 months after interpolation were 5.58-6.60 and 59.43-66.60 mg/l, respectively. Notably, these levels were approximately 2.3-6.6-and 29.7-66.6-fold higher, respectively, than those in fluorochemical plant workers with serum PFC levels of 1-2 mg/l. In the past several decades, PFCs have been ubiquitously used and are being increasingly found in food. This may be causing long-term health problems because of the long half-life and sustained increases in serum PFC levels in adults. Serum PFC levels are positively associated with hyperuricemia, renal toxicity, and impaired renal functioning (Kataria et al., 2015) . Herein, mice subjected to the PFOS challenge had increased levels of Lcn2 (a renal injury marker) and TGFb1 (involved in fibrosis). In addition to the acute effect of PFOS on RTC apoptosis in mice (which we demonstrated previously- Wen et al., 2016) , mice with chronic PFOS exposure also exhibited severe renal damage, including the loss of microvilli and cytoplasm in RTCs, and increases in neutrophil infiltration and the deposition of collagen, glycerol, and lipids in renal tissues. Notably, our findings further highlight the risk of chronic high concentrations of PFOS in renal fibrosis associated with EMT in RTCs. Interestingly, we observed that EMT induction by PFOS is concomitant with cell apoptosis. An explanation as to why PFOS induces these concurrent but distinct events in RTCs might be that offered by different cell-cycle phases, which have been demonstrated by Song (2007) and Yang et al. (2006) , showing that apoptosis and EMT induced by TGF-b1 are closely related to the cell-cycle progression. Whether any causal or interwoven relationship exists between EMT and apoptosis caused by PFOS requires further investigation. In addition, we have reported an association between EMT induction and renal fibrosis in the RTCs of mice subjected to PFOS, and determined that L-carnitine treatment can significantly reduce these effects. These results are in accordance with studies showing that PPARc activation maintains the renal tubular epithelial phenotype and antagonizes renal fibrosis (Zhao et al., 2016) , and those indicating that L-carnitine confers protection against renal fibrosis in hypertensive rats through PPARc activation (Zambrano et al., 2014) . Moreover, increasing evidence has revealed the protective effect of PPARc activation against renal fibrosis. For instance, thiazolidinediones (ie, PPARc ligands) attenuate renal interstitial fibrosis and inflammation by blocking TGF-b (Kawai et al., 2009) . Similarly, our results demonstrated that the induction of TGF-b by PFOS was attenuated by L-carnitine, in addition to the maintenance of the epithelial phenotypes ( Figure 2B ). However, whether chronic PFOS exposure results in renal carcinomas requires further clarification.
In this study, we demonstrated that L-carnitine, NAM, and RGZ prevented cells from EMT induction by restoring Sirt1 and PPARc function in PFOS-treated RTCs. We also confirmed that Lcarnitine can alleviate EMT-associated renal fibrosis in mice chronically subjected to a PFOS challenge. Accordingly, our findings might shed light on the links between Sirt1 and PPARc in renal fibrosis associated with EMT induction and the potency of using L-carnitine for protection.
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